NewsRoom Articles - Page 103 of 154 - PsychedelicNewsWire (PNW)

MondayApr 05, 2021 2:44 pm

Australian Researchers to Conduct Study on Managing Meth Addiction Using Psilocybin

Researchers from Sydney, Australia, are planning a clinical trial with the objective to discover whether administering psychedelics, specifically psilocybin, to individuals who use methamphetamines, commonly known as “meth,” could help manage their addiction. Psilocybin is the active psychedelic ingredient found in magic mushrooms. The scientists from St. Vincent’s Hospital, Darlinghurst, will administer psychedelic therapy to patients who are dependent on ice, or meth. A St. Vincent specialist in toxicology, clinical pharmacology and addiction medicine, lead researcher Dr. Jonathan Brett stated that he was extremely aware of the pressures to carry out the trial in the strictest scientific and ethical boundaries.…

ThursdayApr 01, 2021 12:17 pm

Lumenate App Takes Users on a Trip, Sans Psychedelics

Psychedelics went mainstream a few years ago, and with research on these substances and their therapeutic benefits still ongoing, various jurisdictions across the United States have been considering whether to legalize or decriminalize magic mushrooms as well as other entheogenic fungi and plants. Additionally, more companies are developing psychedelic compounds as consumer products or medications in a bid to profit from the incoming regulatory environment. One of these is Lumenate, a company founded by Jay Conlon and Tom Galea. The two inventors have devised a way to induce a semi-psychedelic state using a device that can be found everywhere in…

WednesdayMar 31, 2021 2:15 pm

Australian Government to Give $15M Grant for Psychedelics Research Focusing on Mental Health

The federal government of Australia will be granting $15 million to clinical studies that look into the use of psychedelics substances such as ecstasy and psilocybin mushrooms for the treatment of mental health conditions. This grant is an important breakthrough in the fight against mental illnesses, especially with nearly half of all adults in Australia set to face mental health issues in the course of their lives. Black Dog Institute, a medical research institute that is dedicated to studying mental health, found that one in five adults experience symptoms of mental conditions in any given year. In the country, that’s…

TuesdayMar 30, 2021 1:30 pm

Tryp Therapeutics (CSE: TRYP) (OTC: TRYPF) Files Provisional Patent for New Psychedelic Delivery Methods

Last week, Tryp Therapeutics issued a statement announcing the submission of a provisional patent to enhance how psychedelics are dispensed across various indications. Tryp Therapeutics is a pharmaceutical company engaged in the development of compounds with known activity and safety profiles for the treatment of rare ailments that currently have no approved treatments. The company has a psilocybin program called the PFN(TM) program that works on developing synthetic psilocybin as a new therapy for specific neuropsychiatric disorders. The patent details new techniques for the development, dosing and delivery of psychedelics, which may help decrease the time a patient spends in…

MondayMar 29, 2021 2:32 pm

Washington D.C. Psychedelics Decriminalization Measure Takes Effect

During the November 2020 elections, voters in Washington, DC, approved a ballot measure that would decriminalize fungi and plant-based entheogens. Last week, the measure came into effect, with a wide range of psychedelic substances such as ayahuasca and psilocybin officially becoming the lowest priority for local law enforcement. Despite this, activists from the Plant Medicine Coalition (“PMC”) who were behind the initiative are now calling for the enactment of additional laws to provide child and worker protections associated with the use of these fungi and plant-based substances. The activists are asking that the city provide guidelines to law enforcement about…

MondayMar 29, 2021 11:54 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Orders First Functional Mushroom Shipment for Global E-Commerce Portal

PULL expands into EU through initial sale of cannabis oil extracts to German pharmaceutical company Sale to Germany expected to pave way for additional supply agreements throughout Europe Company orders first shipment of functional mushroom products for direct-to-consumer e-commerce portal, expects $15,000 gross monthly sales for each formulation PULL’s new state-of-the-art facility constructed to EU GMP standards for worldwide exports With a focus on the cannabis, hemp, functional mushrooms and rapidly emerging psychedelic sectors, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a Canadian plant-based extraction company, is steadily increasing its market share through the achievement of several important…

FridayMar 26, 2021 12:13 pm

Educational App That Demonstrates Psychedelics Effects on the Brain Launches

Psychedelic drugs such as psilocybin mushrooms have been used for centuries in various cultures across the globe before becoming popular in the Western world in the 1960s. Recently, the substances, most of which are naturally occurring substances, have been utilized in research studies in various parts of the world, with the objective being to help develop treatments for various mental health conditions. For instance, a study conducted by researchers from Johns Hopkins Medicine found that two doses of psilocybin produced large and fast reduction in the depressive symptoms of study participants, with some achieving remission through a one month follow-up.…

ThursdayMar 25, 2021 3:00 pm

Lifetime Use of Classic Psychedelics Could Decrease Risk of Hypertension

Research recently reported in “Hypertension” has found that lifetime use of classic psychedelics may be associated with a lower risk of hypertension. Otto Simonsson, from University of Oxford’s department of sociology, stated that the findings demonstrated that classic psychedelic use was linked to a 14% lower chance of hypertension, adding that lifetime use of tryptamine was linked to a 20% lower chance of hypertension. Simonsson and his colleagues noted that these results may be valuable in helping understand the physical health after effects of classic psychedelic use, with randomized controlled trials being conducted to look into the possible ways that…

WednesdayMar 24, 2021 12:15 pm

Seattle Doctor Sues DEA over Psilocybin Mushroom Access for Terminally Ill Patients

A doctor from Seattle who hopes to broaden access to hallucinogenic mushrooms for terminally ill cancer patients is suing the U.S. Drug Enforcement Administration (“DEA”) over its recent denial of an application to legally utilize psilocybin mushrooms in end-of-life treatment. The doctor’s attorneys filed the lawsuit last week in the 9th Circuit’s U.S. Circuit Court of Appeals. They argued that the DEA denying the application was baseless. The attorneys are asking judges to dismiss the decision and force the DEA to reconsider and accommodate reasonable requests made from qualified health practitioners for the therapeutic use of psilocybin. On a press…

TuesdayMar 23, 2021 2:45 pm

Scientists Find Ideal Psychedelic Dose for Use in Psychiatric Treatment

Research that was conducted recently to identify the effects of LSD has been reported in the “Neuropsychopharmacology” journal. The discoveries will be used to plan clinical trials that examine the use of LSD in patients with various psychiatric disorders. Prior research had discovered that LSD could be a treatment for some mental conditions when used in combination with psychotherapy. However, these studies compared LSD doses to placebo. Researchers for the new study focused on testing the effects of LSD in different doses. Matthias E. Liechti, a researcher from the University Hospital Basel, stated that the group or researchers wanted to…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000